TheraGenetics Reports Fourth Quarter and Year-End 2012 Results
2/14/2013 7:06:12 AM
Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2012.
• Consolidated revenue ? $19.1 million in the fourth quarter, down 4% from 2011
? $82.6 million for the year, flat compared with 2011
comments powered by